ALXO

ALX Oncology

This clinical-stage biopharmaceutical company develops novel therapies to treat cancer patients by expanding the possibilities of immuno-oncology and antibody-drug conjugates.

ADXS

The company develops bioengineered immunotherapies and precision small molecule drugs for patients with rare tumors and aggressive cancers.

ALMS

This biopharmaceutical company develops oral therapies to treat patients with immune-mediated diseases, neuroinflammatory conditions and neurodegenerative disorders.

NKIO

This company develops natural killer cell therapies and small molecule medicines to treat solid tumours for patients with cancer and inflammatory diseases.

Aktis Oncology

This biotechnology company develops alpha-emitting radiopharmaceuticals to treat patients with solid tumor cancers.

TPTX

This biopharmaceutical company develops small molecule tyrosine kinase inhibitors to treat patients with advanced solid tumours and lung cancer.

Cullinan Oncology

This company develops therapies for patients living with autoimmune diseases and cancer.

IMGO

This biopharmaceutical company develops small molecule therapies targeting epigenetic enzymes to treat patients with bone marrow diseases and chronic blood cancers.